Does testosterone treatment cause penile growth? This is a common question among men considering testosterone therapy. Testosterone is the primary male sex hormone responsible for sexual development during puberty, including penile growth. However, the relationship between testosterone and penile size is age-dependent and time-sensitive. Once puberty is complete and adult penile size is achieved, typically by late adolescence, testosterone treatment does not cause further structural growth. Understanding when and how testosterone affects penile development is essential for setting realistic expectations about testosterone replacement therapy and recognising when specialist evaluation may be appropriate.

Understanding Testosterone and Penile Development

Testosterone is the primary male sex hormone (androgen) responsible for the development of male sexual characteristics during puberty. Produced predominantly in the testes, testosterone plays a crucial role in the growth and maturation of the penis, scrotum, and other reproductive organs during adolescence. During foetal development and throughout puberty, testosterone levels rise significantly, triggering the physical changes associated with male sexual maturation.

Penile growth occurs primarily during two distinct periods: in utero (before birth) and during puberty, typically between ages 10 and 16. During puberty, rising testosterone levels stimulate the growth of penile tissue, with most growth occurring during Tanner stages 3 and 4 of sexual development. By the end of puberty, typically by late adolescence, the penis reaches its adult size. Unlike long bones, penile tissue does not have growth plates, but the androgen-dependent growth potential is largely exhausted after puberty is complete.

The relationship between testosterone and penile size is therefore age-dependent and time-sensitive. Testosterone (partly through conversion to dihydrotestosterone or DHT) drives external genital development. Adequate testosterone levels during these critical developmental windows are essential for normal penile growth. However, once puberty is complete and adult size is achieved, the structural growth potential of penile tissue is significantly reduced, even though androgen receptors remain active throughout life.

It is important to understand that testosterone affects many aspects of male health beyond genital development, including muscle mass, bone density, red blood cell production, mood, and libido. When considering testosterone therapy for any reason, patients should have realistic expectations about what the treatment can and cannot achieve at different life stages.

Does Testosterone Treatment Cause Penile Growth in Adults?

The short answer is no — testosterone treatment does not cause penile growth in adults who have completed puberty. Once adult penile size has been reached (typically by late adolescence), the tissue no longer responds to testosterone in a way that would promote further structural growth. This is a well-established principle in endocrinology and sexual medicine.

There is no clinical evidence that testosterone replacement therapy (TRT) in adult men increases penile length or girth. Testosterone products are not licensed for penile enlargement in the UK, and this is not a physiologically achievable outcome in adults. Even high doses of testosterone will not stimulate significant penile growth in adults who have completed normal pubertal development.

However, testosterone therapy may have indirect effects that some men perceive as changes in penile size. Men with significantly low testosterone (hypogonadism) may experience:

• Improved erectile function: Better quality erections may make the penis appear larger during arousal

• Reduced suprapubic fat: Weight loss in the pubic area can make the penis more visible

• Increased confidence: Psychological improvements may alter self-perception

• Enhanced libido: Increased sexual interest and function may improve overall sexual satisfaction

According to UK product licences, testosterone replacement therapy is indicated for adult males with confirmed hypogonadism, where low testosterone has been verified by clinical features and biochemical tests. The diagnosis requires both symptoms and repeatedly low testosterone levels. TRT aims to restore testosterone to normal physiological levels to alleviate symptoms such as reduced libido, erectile dysfunction, fatigue, decreased muscle mass, and mood changes. It is not intended or effective for enhancement purposes beyond addressing a clinical deficiency.

When to Speak with Your GP About Testosterone Therapy

If you are experiencing symptoms that may be related to low testosterone, it is important to consult your GP for proper evaluation rather than seeking treatment independently. Symptoms of hypogonadism may include:

• Reduced sexual desire (libido)

• Erectile dysfunction or difficulty maintaining erections

• Persistent fatigue and low energy levels

• Decreased muscle mass and strength

• Increased body fat, particularly around the abdomen

• Mood changes, including depression or irritability

• Reduced bone density (osteoporosis)

• Difficulty concentrating or memory problems

Your GP will take a thorough medical history and arrange appropriate investigations. Diagnosis requires at least two morning blood tests (ideally before 11:00) showing low testosterone levels, along with relevant symptoms. If results are borderline (8-12 nmol/L), additional tests such as sex hormone binding globulin (SHBG) and calculated free testosterone may be helpful. Your GP will also check luteinising hormone (LH), follicle-stimulating hormone (FSH) and prolactin to help determine the cause of low testosterone.

Before starting treatment, baseline assessments typically include prostate-specific antigen (PSA), digital rectal examination (if age-appropriate), haematocrit, and liver function tests. Urgent referral is needed if there are concerns about pituitary disease (headaches, visual disturbances, very low testosterone with high prolactin) or testicular abnormalities.

Important safety considerations: Testosterone therapy is contraindicated in men with known or suspected prostate cancer or male breast cancer. It should be used with caution in men with severe cardiac, hepatic or renal insufficiency, and should be withheld if haematocrit reaches 54% or higher. Treatment requires regular monitoring of testosterone levels, haematocrit and PSA (at 3-6 months initially, then annually).

TRT can suppress sperm production and should be avoided by men trying to conceive; alternative treatments may be considered in these cases. It is crucial to avoid purchasing testosterone products online or from unregulated sources, as these may be counterfeit, contaminated, or contain incorrect doses. If you experience side effects from prescribed testosterone, report them through the MHRA Yellow Card scheme.

Testosterone Therapy in Adolescents and Growth Considerations

The situation differs significantly in adolescents who have not yet completed puberty. In young males with delayed puberty or hypogonadism diagnosed during adolescence, testosterone therapy may be prescribed to initiate or support normal pubertal development, including penile growth. This represents a fundamentally different clinical scenario from treating adults.

Delayed puberty is typically defined as the absence of testicular enlargement by age 14 or failure to complete pubertal development within five years of its onset. Causes may include constitutional delay (a normal variant where puberty occurs later), hypogonadism (insufficient testosterone production), or chronic medical conditions. When testosterone deficiency is confirmed, carefully monitored testosterone therapy can help stimulate the physical changes of puberty, including growth of the penis, development of pubic and body hair, voice deepening, and increased muscle mass.

It's important to note that the effect on testicular growth depends on the underlying diagnosis. In primary hypogonadism, testosterone therapy may not increase testicular volume, while in hypogonadotropic hypogonadism, alternative treatments such as human chorionic gonadotropin (hCG) may be considered when testicular growth and future fertility are priorities.

Specialist paediatric endocrinology input is essential in these cases. Treatment protocols for adolescents differ substantially from adult TRT, with careful attention to:

• Appropriate dosing for age and developmental stage

• Monitoring of growth velocity and bone maturation

• Assessment of pubertal progression using Tanner staging

• Regular review of testosterone levels and treatment response

• Psychological support during development

The timing and duration of treatment are critical. Starting testosterone therapy too early or at inappropriate doses can lead to premature closure of growth plates in long bones, potentially limiting final adult height. Conversely, untreated hypogonadism during adolescence can result in incomplete sexual development and associated psychological distress.

Parents and adolescents should be aware that testosterone therapy in this context is aimed at achieving normal pubertal development, not enhancing growth beyond normal parameters. Treatment is carefully calibrated to mimic natural puberty as closely as possible. Any concerns about pubertal development should be discussed with your GP, who can arrange appropriate referral to paediatric endocrinology services.

Frequently Asked Questions